Proto Axiom — Full Portfolio
9 tracked investments · listed companies and verified rows first
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsBain Capital Life SciencesCatalio Capital Management, LPSV Health InvestorsTenmileAbingworthAlly Bridge Group+2 more
ProtoAxiom is an investment and company-building firm focused on Australian life science companies.
BiotechDeep TechSydney, AU
Floaxiom develops NanoSurface, a biologically manufactured affinity nanoparticle platform for antibody (mAb) purification, offering a chromatography-free alternative to protein A resin columns and membrane systems.
BiotechDeep TechNew Materials
HealthtechChestnut Hill, US
Lindsay E. Wu(Executive Officer, Director)inDavid Sinclair(Director)Michael Sistenich(Director)Hayden Homer(Director)Alexander Tristan Edwards(Director)
Co-investorsLife Biosciences
Therapeutics company formed from Australian translational science, with a topical antifungal lead in Phase IIb; supported by Proto Axiom's operating bench.
Platform opportunity sourced from UNSW; Proto Axiom co-creator focused on platform commercialisation strategy and team building.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.